Emily Meehan practices in the area of corporate law. Ms. Meehan is a 2020 cum laude graduate of Temple University Beasley School of Law, where she was the recipient of the Jack M. Golden and Frieda Golden Prize, and a cum laude graduate of St. Joseph's University.
- Temple University Beasley School of Law, J.D., cum laude, 2020
- Recipient of the Jack M. Golden and Frieda Golden Prize
- St. Joseph's University, B.A., cum laude, 2017
- Duane Morris LLP
- Associate, 2021-present
Represented Element Dental (fka Mid-Atlantic Dental), a portfolio company of a fund sponsored by SC Goldman, in connection with its merger with Sonrava Health (fka Western Dental), a portfolio company of a fund sponsored by New Mountain Capital; the merger created a diversified dental support organization (DSO) offering dental services through 572 offices in 20 states.
Advised Market Street Advisors, Inc. dba Archer®, a technology-enabled service provider to the investment management industry, in a leveraged recapitalization that included a growth investment by LLR Partners, the redemption of NewSpring Capital’s investment, a loan facility from Silicon Valley Bank and a corporate restructuring.
Advised CMS Technologies, Inc. dba Prevenio®, a leading provider of innovative food safety solutions primarily for protein and produce industries, in its $170 million acquisition by JBT Corporation (NYSE: JBT), a global technology solutions provider to high-value segments of the food and beverage industry.
Represented StoneMor Inc. in its sale of $400 million in senior secured notes to Jefferies LLC as initial purchaser in a Rule 144A private placement transaction; the notes were guaranteed by more than 125 StoneMor subsidiaries operating in 24 states and Puerto Rico.
Represented Allevi, Inc., a manufacturer of 3D bioprinters and bioinks trusted by leading researchers worldwide, in the $9.5 million sale of its business to 3D Systems (NYSE: DDD), a provider of 3D printing and digital manufacturing solutions.
Represented Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced pharmaceutical delivery technologies, development, and manufacturing solutions with market cap in excess of $17 billion, in its $80 million “carve-out” acquisition of the manufacturing and packaging operations of Acorda Therapeutics, Inc. (Nasdaq: ACOR), a neurological disorder therapy manufacturer and developer in Massachusetts, operating best-in-class spray drying capacity; the acquisition complemented Catalent’s status as a premier U.S.-based partner for companies across dry powder inhaled dose forms.